<DOC>
	<DOCNO>NCT01913301</DOCNO>
	<brief_summary>The purpose study gather information regard safety effectiveness investigational drug call Alagebrium use treat Heart Failure relation exercise tolerance 6 month trial .</brief_summary>
	<brief_title>A Randomized Double-Blind , Placebo-Controlled , Multiple-Dose Study Evaluate Effects Alagebrium Exercise Subjects With Diastolic Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Heart Failure , Diastolic</mesh_term>
	<criteria>1 . Males females 50 year age old . 2 . Diagnosis diabetes OR diagnosis hypertension require therapy . 3 . Echocardiographic ejection fraction ≥ 45 % verify within 1 year prior baseline , assume intercurrent cardiac event echo screening . 4 . Echocardiographic evidence diastolic dysfunction define E/E ' ≥ 12 determine within 1 year prior baseline ; sinus rhythm required time echo . 5 . Previous hospitalization due heart failure OR current previous BNP ≥ 100 pg/mL . 6 . New York Heart Association ( NYHA ) functional class IIIV . 7 . At least 1 month hospitalization heart failure randomization . 8 . Stable dos heart failure medication ( diuretic , ACE inhibitor , ARB 's , betaadrenergic antagonist , aldosterone antagonist ) least 1 month prior randomization . 9 . Able understand content willing provide write informed consent . 10 . Agree use adequate contraception study premenopausal . 1 . Ejection fraction &lt; 45 % . 2 . Screening Sixminute walk test &gt; 450 meter &lt; 100 meter 3 . Clinically significant cardiac valvular disease ( mitral regurgitation ( MR ) &gt; grade I , aortic insufficiency ( AI ) &gt; grade 1 , mitral stenosis ( MS ) , aortic stenosis ( AS ) ) . 4 . History stroke , sequelae transient ischemic attack ( TIA ) , reversible ischemic neurological defect ( RIND ) within 6 month prior screen . 5 . History acute myocardial infarction within 6 month prior screen . 6 . Severe COPD define O2 steroid dependence . 7 . History systemic inflammatory collagen vascular disease . 8 . Active treat malignancy within 12 month prior Visit 1 exception basal cell carcinoma . 9 . Any significant systemic illness ( e ) medical condition ( ) could lead difficulty comply protocol ; concurrent condition ( ) , investigator 's opinion , would prohibit subject complete study , would best interest subject . 10 . Estimated glomerular filtration rate ( GFR ) ≤ 30 mL/min/1.73m² calculate Modification Diet Renal Disease ( MDRD ) study equation [ MDRD = 186 X serum creatinine ( mg/dl ) 1.154 X year 0.203 X ( 0.742 female ) X ( 1.210 African American ) ] . 11 . Liver function test ( SGOT and/or SGPT ) &gt; 2.5 time upper limit normal range . 12 . Hb &lt; 10 g/dL . 13 . Use investigational drug ( ) within 30 day prior screen . 14 . Previous exposure alagebrium . 15 . Known seropositivity HIV hepatitis C , presence hepatitis B surface antigen . 16 . Pregnancy active breastfeeding . Urine pregnancy test perform woman postmenopausal least 1 year .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>